Did you present at #AAIC25 in Toronto last year?

Check out your published abstracts now live in A&D!!

#AlzResearch

#AAIC25 Abstracts are now published in Alzheimer's & Dementia, the official journal of the
@alzassociation.bsky.social!

Please check out this thread to find your published abstract based on scientific focus area.

Congratulations to all presenters at #AAIC25!💜

#AlzResearch

🗓️ In case you missed it: At #AAIC25, the World Dementia Council and @alzassociation.bsky.social convened a powerful dialogue on advancing advocacy. The September @alzdemjournals.bsky.social issue reflects on the discussion: bit.ly/47PmkWJ

📰 Our latest update is live in @alzdemjournals.bsky.social. This month we reflect back on our #AAIC25 Advocacy Breakfast held in partnership with the @alzassociation, on turning scientific breakthroughs into global advocacy. Read more: bit.ly/47PmkWJ

FTD impacts care partners too with stress, lost income & financial strain.

At #AAIC25, the FTD Disorders Registry showed how misdiagnosis & delays deepen that burden: ftdregistry.org/press/regist...

This #WorldFTDAwarenessWeek, let’s honor care partners & push for faster diagnoses.

Scientists Say These Daily Routines Can Slow Cognitive Decline A new study documents the benefits of lifestyle changes that can keep the brain young.

September is #HealthyAgingMonth, & we have stronger evidence than ever that healthy behaviors can protect brain health. 🧠

U.S. POINTER study results, reported at #AAIC25, showed that a structured lifestyle program can slow cognitive aging in at-risk adults. bit.ly/3Jd4z9j

Arturo X. Pereiro e David Facal, desprazáronse un ano mais á conferencia #aaic25 (Alzheimers’ Association). En Toronto puideron presentar varios traballos do seu estudo de cohorte “Compostela Aging Study” (CompAS), e manter xuntanzas de traballo con colegas cos e coas que colaboran asiduamente.

At #AAIC25, PMC Co-Director Dr. Jason Karlawish called out a paradox: “Spectacular progress… but a policy infrastructure that is unscientific and hostile.”

In a bonus episode of The Age of Aging, he reflects on funding cuts, biomarkers, and new therapies.
🎧 Listen here: bit.ly/3Jz6W6K

First Glimmers of Lecanemab Efficacy in the “Real World”? | ALZFORUM

At #AAIC25, Dr. Christopher Brown shared early real-world results of lecanemab. Using personalized disease trajectories, his team found slowed decline after a year of treatment while also flagging nonresponders. Attendees called the data “remarkable.”

In #Alzheimers news: “4 years on #lecanemab, the benefit tripled” … “3 years on #donanemab, the benefit doubled”, as summed by @Alzforum from #AAIC25 reported data. How the graphical illusion hides the acceleration of cognitive decline (9-part thread).
www.alzforum.org/news/confere...

Plenary Perspectives: What We Learned at AAIC 2025 - DEMENTIA RESEARCHER ISTAART Ambassadors Jinhak Kim, Xue-Rui Peng, Ziphozihle Ntwatwa, and Ireneaus Nyame share reflections on key AAIC 2025 plenary sessions in dementia research.

Catch-up with @istaart.bsky.social Ambassadors Jinhak Kim, Xue-Rui Peng, Ziphozihle Ntwatwa, and Ireneaus Nyame sharing reflections on key #AAIC25 plenary sessions.

www.dementiaresearcher.nihr.ac.uk/plenary-pers...

Expanding the Presence of the ALZpath Blood Test in Alzheimer Disease Research: Mike Banville At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WA...

At this year’s #AAIC25, ALZpath CEO Mike Banville joined NeurologyLive to discuss how the ALZpath proprietary #pTau217 antibody is powering blood-based testing to enable earlier, scalable Alzheimer’s disease detection. 🧠💜

📌Watch the full interview here: www.neurologylive.com/view/expandi...

Join our LIVE Podcast recording at 2pm BST today, to hear from @istaart.bsky.social Ambassadors summarising and reflecting on this years #AAIC25 plenary talks.

youtu.be/otZkJWqHedY

In a new blog from WDC Chair Joanne Pike and Executive Director Lenny Shallcross, they reflect on #AAIC25. New diagnostics, treatments and U.S. POINTER results show a pivotal moment for dementia. Now, advocacy must deliver this science to patients. Read more: bit.ly/4osk4up

🔁 ICYMI at #AAIC25:

TIME-AD presented new research on whether removing amyloid from the brain can accurately predict declines in cognition and functioning.

📖 Read the preprint to learn more: www.medrxiv.org/content/10.1...

#TIMEAD #EpiSky

The Hidden Realities of Dementia in Underrepresented Communities ISTAART Voices · Episode

As we return from #AAIC25, we’re reflecting back on #ISTAART Voices podcast episodes to keep the conversation going! Revisit our very first episode where Dr. Sharon Sanz Simon discusses the challenges in underrepresented dementia research.

Listen now: open.spotify.com/episode/35yomfdS0zZhesdkESKpBr

A researcher is standing next to their research poster at a scientific conference, they are smiling and holding a coffee. The title of the poster is Predicting Delayed Diagnosis in Dementia: The Impact of Coping Style.

PhD student @isaac-dc.bsky.social had a great time in Toronto at their first @alzassociation.bsky.social‬ international conference. They enjoyed learning about new community-based interventions and co-designed respite programs, as well as presenting their own research and lots of poutine! #AAIC25

Congratulations, and thank you for bringing your work to #AAIC25!

Exposure To Leaded Fuel Affects Memory Loss Of Older Americans - Health Policy Watch Americans are about 20% more likely to experience memory problems if they lived in areas with high levels of atmospheric lead, according to a study of over

Exposure to Leaded Fuel Affects Memory Loss of Older Americans

Research suggests half of the US population – more than 170 million people – were exposed to high lead levels in early childhood.

✍️ @kerrycullinan.bsky.social
@alzassociation.bsky.social @jama.com
@topublichealth.bsky.social #AAIC25

#Toronto #AAIC25

A CAN community member attended #AAIC25 in Toronto, where experts shared: new blood-based biomarker guidelines, promising Lecanemab & Donanemab results, and lifestyle insights from the U.S. POINTER trial. More here: www.feinberg.northwestern.edu/sites/autism...

Last month CCANDL presented at #AAIC25
Madeline, Deling, & Dr. Mueller presented posters on their recent projects. Deling gave a talk about TBIs and their relation to AD risk factors. They had an amazing time connecting with other #ADRD researchers and look forward to next year!

It’s been about a week since #AAIC25, and I’m finally taking a moment to reflect on what an amazing experience it was. I learned so much, had great conversations, and left feeling inspired by all the incredible work happening in the field. Grateful for the chance to be part of it all!

Thank you all for being a part of #AAIC25!

AAIC 2025: The future of Alzheimer’s research is here - Alzheimer's Research UK Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for earlier diagnosis.

We had a great time at #AAIC25 last week, and it was brilliant to catch up with so many of you in Toronto!
From long-term trial data to new delivery methods and diagnostic tools, find out more about our conference highlights: www.alzheimersresearchuk.org/news/aaic-20...

Nous sommes heureux d'annoncer que l'affiche d'Eden Mancor, stagiaire du CCNV, a été l'une des gagnants du concours d'affiches étudiantes de
@istaart.bsky.social de la Conférence internationale de l'Association Alzheimer.

Félicitations, Eden, pour cette réussite remarquable !

#AAIC25

We’re happy to share that, CCNA trainee, Eden Mancor’s poster “The role of reserve in cognition, gait, & responsivity to interventions for mild cognitive impairment”, was one of the
@istaart.bsky.social student poster competition winners at #AAIC25
Congrats, Eden, on this major achievement🎉

Fluid & Neuroimaging Biomarkers Forum Fluid & Neuroimaging Biomarkers Forum

🚨 New pilot event! Fluid and Neuroimaging Biomarker Forum – Friday 8 Aug, 12pm BST. Researcher-led discussion of #AAIC25 findings and emerging methods. Join the room live.

communities.dementiaresearcher.nihr.ac.uk/c/live-poste...

Access our #AAIC25 posters below.

• Whole Brain Measurement of Amyloid Plaques and Neuroinflammation in AD Model Mice: tinyurl.com/amyloid-plaq...

• Brain-Wide Cellular-Resolution Measurement of Antibody Therapeutic Biodistribution: tinyurl.com/antibody-the...

Thank you for joining us at #AAIC25 in #Toronto. CEO Damian Wheeler presented two posters, "Whole Brain Measurement of Amyloid Plaques and Neuroinflammation in AD Model Mice" and "Brain-Wide Cellular-Resolution Measurement of Antibody Therapeutic Biodistribution."